EA201300310A1 - Применение агонистов аденозиновых а1-рецепторов для лечения глаукомы и внутриглазной гипертензии - Google Patents

Применение агонистов аденозиновых а1-рецепторов для лечения глаукомы и внутриглазной гипертензии

Info

Publication number
EA201300310A1
EA201300310A1 EA201300310A EA201300310A EA201300310A1 EA 201300310 A1 EA201300310 A1 EA 201300310A1 EA 201300310 A EA201300310 A EA 201300310A EA 201300310 A EA201300310 A EA 201300310A EA 201300310 A1 EA201300310 A1 EA 201300310A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glaucoma
treatment
hypertension
adenosine
agonists
Prior art date
Application number
EA201300310A
Other languages
English (en)
Other versions
EA028411B1 (ru
Inventor
Юрген Клар
Жорж Фон Дегенфельд
Ханс-Георг Лерхен
Барбара Альбрехт-Кюппер
Андреас Кнорр
Петер Занднер
Даниель Майбом
Original Assignee
Байер Интеллектчуал Проперти Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Интеллектчуал Проперти Гмбх filed Critical Байер Интеллектчуал Проперти Гмбх
Publication of EA201300310A1 publication Critical patent/EA201300310A1/ru
Publication of EA028411B1 publication Critical patent/EA028411B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Настоящее изобретение относится к применению селективных агонистов аденозиновых А1-рецепторов, в частности дицианопиридинам формулы (I), для лечения и/или профилактики глаукомы, нормотензивной глаукомы и внутриглазной гипертензии, а также их применения для изготовления лекарственного препарата для лечения и/или профилактики глаукомы и внутриглазной гипертензии.
EA201300310A 2010-09-02 2011-08-29 Применение агонистов аденозиновых а1-рецепторов для лечения глаукомы и внутриглазной гипертензии EA028411B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10175151 2010-09-02
PCT/EP2011/064829 WO2012028585A1 (en) 2010-09-02 2011-08-29 Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension

Publications (2)

Publication Number Publication Date
EA201300310A1 true EA201300310A1 (ru) 2013-08-30
EA028411B1 EA028411B1 (ru) 2017-11-30

Family

ID=44582992

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300310A EA028411B1 (ru) 2010-09-02 2011-08-29 Применение агонистов аденозиновых а1-рецепторов для лечения глаукомы и внутриглазной гипертензии

Country Status (30)

Country Link
US (3) US20120058983A1 (ru)
EP (1) EP2611415B1 (ru)
JP (1) JP5875585B2 (ru)
KR (1) KR20140091457A (ru)
CN (1) CN103249400B (ru)
AP (1) AP3413A (ru)
AU (1) AU2011298430B2 (ru)
BR (1) BR112013005224A2 (ru)
CA (1) CA2809700A1 (ru)
CL (2) CL2013000599A1 (ru)
CR (1) CR20130094A (ru)
CY (1) CY1117458T1 (ru)
DK (1) DK2611415T3 (ru)
EA (1) EA028411B1 (ru)
ES (1) ES2570659T3 (ru)
HK (1) HK1188138A1 (ru)
HR (1) HRP20160532T1 (ru)
HU (1) HUE027295T2 (ru)
MA (1) MA34489B1 (ru)
MX (1) MX2013002396A (ru)
MY (1) MY160383A (ru)
NZ (1) NZ607624A (ru)
PL (1) PL2611415T3 (ru)
RS (1) RS54743B1 (ru)
SG (1) SG187974A1 (ru)
SI (1) SI2611415T1 (ru)
TW (1) TWI516266B (ru)
UA (1) UA111947C2 (ru)
WO (1) WO2012028585A1 (ru)
ZA (1) ZA201302340B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014009086A (es) 2012-01-26 2015-06-05 Inotek Pharmaceuticals Corp Polimorfos anhidros de nitrato de [ (2r,3s,4r,5r) -5- (6- (ciclopentilamino) -9h-purin-9-il) -3,4-dihidroxitetra-hidrofuran- 2-il) ] metilo y procesos para su preparación.
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
AU2014363705A1 (en) * 2013-12-12 2016-06-30 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists as medicaments against renal diseases
AU2015205268B2 (en) * 2014-01-10 2019-03-14 Santen Pharmaceutical Co., Ltd. Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
JP2018516882A (ja) * 2015-05-06 2018-06-28 バイエル・ファルマ・アクティエンゲゼルシャフト ２−｛４−［２−（｛［２−（４−クロロフェニル）−１，３−チアゾール−４−イル］メチル｝スルファニル）−３，５−ジシアノ−６−（ピロリジン−１−イル）ピリジン−４−イル］フェノキシ｝エチル−ｌ−アラニル−ｌ−アラニネート一塩酸塩を調製する方法
WO2017137528A1 (en) 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Adenosine a1 receptor agonist for use in treatment of status epilepticus
CN112545983A (zh) * 2020-12-18 2021-03-26 合肥中龙神力动物药业有限公司 一种复方硫酸新霉素滴眼液及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052510A (en) 1974-12-18 1977-10-04 Sandoz, Inc. 4-alkyl-2,6-di(secondary or tertiary alkylamino) pyridines, compositions thereof and methods for treating diabetes and obesity
TW299333B (ru) 1992-12-29 1997-03-01 Takeda Pharm Industry Co Ltd
DE4334919A1 (de) * 1993-10-13 1995-04-20 Liedtke Pharmed Gmbh Grenzwertig wirksame Arzneiformen mit Betablockern
CA2192820C (en) 1994-06-16 2000-11-28 Yuhpyng L. Chen Pyrazolo and pyrrolopyridines
DE4430638A1 (de) 1994-08-29 1996-03-07 Bayer Ag Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel
JPH09132529A (ja) 1995-11-09 1997-05-20 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
IL125071A0 (en) 1996-01-17 1999-01-26 Novo Nordisk As Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives their preparation and use
EP2311806A3 (en) 1996-01-29 2011-08-10 The United States of America, Represented by the Secretary, Department of Health and Human Services Dihydropyridine-, pyridine-, benzopyranone- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists
JPH10324687A (ja) 1997-02-19 1998-12-08 Nippon Soda Co Ltd ピロール化合物、製法および農園芸用殺菌剤
US6191280B1 (en) 1997-05-30 2001-02-20 Basf Aktiengesellschaft Method for producing substituted thiopyridines
CA2294830A1 (en) 1997-07-16 1999-01-28 John Bondo Hansen Fused 1,2,4-thiadiazine derivatives, their preparation and use
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
AU780527B2 (en) 2000-02-25 2005-03-24 F. Hoffmann-La Roche Ag Adenosine receptor modulators
EP1302463A1 (en) 2000-07-18 2003-04-16 Yamanouchi Pharmaceutical Co. Ltd. Medicine comprising dicyanopyridine derivative
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002048115A2 (en) 2000-12-11 2002-06-20 E. I. Du Pont De Nemours And Company Quinazolinones and pyridinopyrimidinones for controlling invertebrate pests
HUP0303538A2 (hu) 2000-12-21 2005-02-28 Bristol-Myers Squibb Co. Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10134481A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
JP2003183254A (ja) 2001-12-20 2003-07-03 Yamanouchi Pharmaceut Co Ltd ２−アシルアミノ−３，５−ジシアノピリジン誘導体又はその塩
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1388342A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7186716B2 (en) 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
MXPA05006367A (es) 2002-12-12 2005-08-29 Pharmacia Corp Metodo de uso de compuestos de aminocianopiridina como inhibidores de cinasa-2 de proteina activada de cinasa de proteina activada por mitogeno.
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1667683A4 (en) 2003-09-23 2009-04-29 Merck & Co Inc INHIBITORS OF POTASSIUM CHANNELS WITH QUINOLINE
CA2545258A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
BRPI0512514A (pt) 2004-06-25 2008-03-11 Taisho Pharmaceutical Co Ltd composto, antagonista para receptores de crf, e, uso de um composto
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
DE102004032651A1 (de) * 2004-07-06 2006-02-16 Bayer Healthcare Ag Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen
EP1827438B2 (en) 2004-09-20 2014-12-10 Xenon Pharmaceuticals Inc. Piperazin derivatives for inhibiting human stearoyl-coa-desaturase
CA2602514A1 (en) 2005-03-24 2006-09-28 Bayer Healthcare Ag Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
US20100009973A1 (en) 2006-04-28 2010-01-14 Avexa Limited Integrase Inhibitors 3
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
JP2008266143A (ja) 2007-04-16 2008-11-06 Santen Pharmaceut Co Ltd アデノシン誘導体を有効成分として含有する緑内障治療剤
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036075A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Ag Prodrugs und ihre Verwendung
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
WO2009143992A1 (de) 2008-05-29 2009-12-03 Bayer Schering Pharma Aktiengesellschaft 2-alkoxy-substituierte dicyanopyridine und ihre verwendung
DE102008062566A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Aminosäureester-Prodrugs und ihre Verwendung
DE102008062561A1 (de) * 2008-12-16 2010-06-24 Maxon Motor Ag Bausatz für einen Elektromotor mit einem Drehwinkelgeber
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
SG175346A1 (en) * 2009-05-01 2011-11-28 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans

Also Published As

Publication number Publication date
SI2611415T1 (sl) 2016-06-30
ES2570659T3 (es) 2016-05-19
MA34489B1 (fr) 2013-08-01
EP2611415A1 (en) 2013-07-10
NZ607624A (en) 2014-10-31
US20120058983A1 (en) 2012-03-08
PL2611415T3 (pl) 2016-08-31
AU2011298430A1 (en) 2013-03-21
HK1188138A1 (en) 2014-04-25
AP2013006753A0 (en) 2013-02-28
MY160383A (en) 2017-03-15
JP2013536819A (ja) 2013-09-26
TW201212926A (en) 2012-04-01
ZA201302340B (en) 2015-11-25
EP2611415B1 (en) 2016-02-24
DK2611415T3 (en) 2016-05-23
AP3413A (en) 2015-09-30
RS54743B1 (sr) 2016-10-31
CA2809700A1 (en) 2012-03-08
KR20140091457A (ko) 2014-07-21
CN103249400A (zh) 2013-08-14
CR20130094A (es) 2013-07-01
SG187974A1 (en) 2013-04-30
WO2012028585A1 (en) 2012-03-08
HRP20160532T1 (hr) 2016-06-17
CY1117458T1 (el) 2017-04-26
BR112013005224A2 (pt) 2016-05-03
EA028411B1 (ru) 2017-11-30
US20150306084A1 (en) 2015-10-29
JP5875585B2 (ja) 2016-03-02
CL2013000599A1 (es) 2013-08-09
US20130210797A1 (en) 2013-08-15
CN103249400B (zh) 2015-04-22
HUE027295T2 (en) 2016-10-28
UA111947C2 (uk) 2016-07-11
US9040566B2 (en) 2015-05-26
CL2016001164A1 (es) 2016-12-23
MX2013002396A (es) 2013-04-03
TWI516266B (zh) 2016-01-11
AU2011298430B2 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
CY1124311T1 (el) Παρεμποδιστες dna-pk
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
EA201300310A1 (ru) Применение агонистов аденозиновых а1-рецепторов для лечения глаукомы и внутриглазной гипертензии
EA201790515A1 (ru) Противовирусные соединения
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA201390576A1 (ru) Противовирусные соединения
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201490947A1 (ru) Производные пурина для лечения вирусных инфекций
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
MX2013001204A (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
EA201071329A1 (ru) Диамидные производные адамантана и их применение
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
EA201491002A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
EA201490037A1 (ru) Антагонисты trpv4
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
EA201401259A1 (ru) Фторированные мостиковые производные спиро[2,4]гептана в качестве агонистов рецептора alx
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
EA201201623A1 (ru) Лечение диабета 2 типа

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU